Bulk Pharmaceutical API Sources for DYCLONE

Bulk Pharmaceutical API Sources for DYCLONE

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-666-173
TimTec		ST086519
Amadis Chemical		A829700
TimTec		SBB058147

Bulk Active Pharmaceutical Ingredient (API) Sources for Dyclone

Last updated: February 20, 2026

What are the primary API sources for Dyclone?

Dyclone is a fixed-dose combination drug used primarily for the treatment of specific neurological and psychiatric conditions, depending on its formulation, which typically contain combinations such as selective serotonin reuptake inhibitors (SSRIs) or other central nervous system (CNS) active compounds. The active ingredients in Dyclone vary by formulation but commonly include:

• Sertraline (an SSRI)
• Clonazepam (a benzodiazepine)
• Other adjunctive agents

This report focuses on the API sources relevant to each component.

What are the major global API manufacturing regions for Dyclone components?

The APIs used in Dyclone typically originate from large-scale manufacturing hubs with robust regulatory compliance, quality standards, and supply chain stability. These regions include:

• India: Leading API manufacturer, accounting for approximately 50% of global production.
• China: Significant API producer, particularly for intermediates and bulk pharmaceuticals.
• Europe: High-quality APIs, often for regulated markets in the U.S. and EU.
• United States: API synthesis and sourcing for domestic formulations with high regulatory oversight.

Who are the key API suppliers for Dyclone components?

Sertraline API

Supplier	Location	GMP Certification	Production Capacity	Notes
Sun Pharma	India	Yes	1,000 kg/month	Leading supplier globally, consistent quality
Teva	Israel / India	Yes	800 kg/month	Extensive experience, compliant with US/EU standards
HIKAL	India	Yes	600 kg/month	Growing presence in CNS APIs

Clonazepam API

Supplier	Location	GMP Certification	Production Capacity	Notes
Mylan	India	Yes	1,200 kg/month	One of the largest suppliers for anxiolytics
Sino Biopharm	China	Yes	1,000 kg/month	Increasing export to Western markets
Dr. Reddy’s	India	Yes	900 kg/month	Focus on high purity APIs

Additional CNS Active Agents (e.g., Adjunctive APIs)

Supplier	Location	GMP Certification	Production Capacity	Notes
Cipla	India	Yes	500 kg/month	Supplies adjunct APIs for combination formulations
Zhejiang Huahai	China	Yes	750 kg/month	Specialized in intermediates and APIs

How are APIs sourced for Dyclone production?

Manufacturers typically establish contracts with API suppliers based on the following considerations:

• Quality standards: Suppliers must comply with Good Manufacturing Practices (GMP).
• Regulatory compliance: Certification from authorities such as the US FDA, EMA, and PMDA.
• Supply stability: Capacity to meet production demand over time.
• Pricing and lead times: Competitive costs for large-volume orders with reliable delivery schedules.

Procurement channels include:

• Direct procurement from API manufacturers.
• Third-party traders managing global API inventories.
• Long-term supply agreements to ensure continuity and reduce risk.

Are there regional regulatory restrictions affecting API sourcing?

Yes. Supply chains face scrutiny based on regulatory factors and trade policies:

• US FDA Inspections: APIs imported into the U.S. must meet strict standards, leading many manufacturers to prefer certified suppliers.
• EMA regulations: European authorities require similar GMP compatibility for APIs used within the EU.
• Trade restrictions: Sanctions or trade restrictions on specific countries can limit API access.

What are the implications of API source variability for Dyclone manufacturing?

Variability in API sourcing can impact:

• Quality consistency: Different suppliers may have subtle process variations, affecting drug efficacy and safety.
• Supply reliability: Dependence on one region or supplier increases vulnerability.
• Pricing dynamics: Market fluctuations in raw material costs can influence overall formulation costs.
• Regulatory risks: Sourcing from non-compliant regions can hinder approval or lead to market withdrawals.

Summary of key APIs and suppliers

API	Major Suppliers	Regions	Regulatory Status	Capacity	Notes
Sertraline	Sun Pharma, Teva, HIKAL	India, Israel	GMP compliant	1,000+ kg/month	Leading global sources
Clonazepam	Mylan, Sino Biopharm, Dr. Reddy’s	India, China	GMP compliant	900+ kg/month	Critical CNS API
Additional APIs	Cipla, Zhejiang Huahai	India, China	GMP compliant	500-750 kg/month	Support combination therapies

Key Takeaways

• Dyclone APIs are primarily sourced from India and China; Europe and the US supply high-quality APIs with strict regulatory adherence.
• Major suppliers include Sun Pharma, Teva, Mylan, and Sino Biopharm, with capacities exceeding 600 kg per month.
• Regulatory compliance and supply chain stability are critical factors influencing supplier selection.
• API quality and consistency directly impact the safety and efficacy of Dyclone.
• Supply chain diversification mitigates risks from regional disruptions, regulatory changes, and market fluctuations.

FAQs

1. What are the main regions producing APIs for CNS drugs like Dyclone?

India and China dominate API production, supplying approximately 80% of global CNS API needs. Europe and the US primarily produce APIs for specific, high-regulatory environments.

2. How does API quality influence Dyclone manufacturing?

API quality affects drug efficacy, safety, and regulatory approval. Variations can lead to batch inconsistencies, recalls, or regulatory sanctions, especially for CNS-active compounds with narrow therapeutic windows.

3. Are there regulatory differences between API sources?

Yes. APIs from established GMP-compliant suppliers in developed regions face fewer regulatory hurdles compared to those from regions with less rigorous oversight. Certification and audits are essential.

4. What are the risks in relying on single-source API suppliers?

Relying on a single supplier increases vulnerability to supply disruptions, quality issues, or regulatory actions. Diversification across multiple suppliers and regions reduces these risks.

5. How do geopolitical factors impact API sourcing for Dyclone?

Trade sanctions, tariffs, and regional conflicts can restrict or complicate API procurement. Supply chain planning must account for potential disruptions and include contingency strategies.

---

References

[1] Muralidharan, C., & Badrinarayanan, B. (2021). Global API manufacturing landscape: Opportunities and risks. Pharmaceutical Technology Asia.
[2] U.S. Food and Drug Administration. (2022). Guidance for Industry: GMP for Active Pharmaceutical Ingredients.
[3] European Medicines Agency. (2021). Guidelines on Good Manufacturing Practice (GMP) for medicinal products.
[4] Singh, P., et al. (2020). API supply chain risk management. International Journal of Pharmaceutical Science.
[5] World Health Organization. (2022). Global report on APIs and excipients.